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Abstract 
Chloroquine and hydroxy-chloroquine already established as anti-malarial and lupus drugs have recently 
gained renewed attention in the fight against the Covid-19 pandemic. Bio-mimetic HPLC methods have 
been used to measure the protein and phospholipid binding of the racemic mixtures of the drugs. The 
tissue binding and volume of distribution of the enantiomers have been estimated. The enantiomers can 
be separated using Chiralpak AGP HPLC columns. From the α-1-acid-glycoprotein (AGP) binding, the lung 
tissue binding can be estimated for the enantiomers. The drugs have a large volume of distribution, 
showed strong and stereoselective glycoprotein binding, medium-strong phospholipid-binding indicating 
only moderate phospholipidotic potential, hERG inhibition and promiscuous binding. The drug efficiency of 
the compounds was estimated to be greater than 2 % which indicates a high level of free biophase 
concentration relative to dose. The biomimetic properties of the compounds support the well-known 
tolerability of the drugs. 
©2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Chloroquine (CQ) and hydroxy-chloroquine (HCQ) are well established for the treatment of malaria, 
rheumatoid arthritis, and lupus. CQ was first synthesised in 1934 by Hans Andersag at Bayer in Elberfeld 
Germany, by modifying the chemical structure of quinine an anti-malarial natural alkaloid [1]. During the 
Second World War, when millions of soldiers were taking CQ for malaria prevention, its beneficial effects 
were discovered in the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). 
When the resistance of CQ against malaria plasmids became apparent, the search for analogues resulted in 
the discovery of HCQ in 1945 [1]. The activity of CQ against viruses was first reported in 1972. by Shimizu et 
al. [2]. More than ten years ago, CQ was proposed as a broad-spectrum antimicrobial agent against 
bacteria, fungal and viral infections [3]. In December 2019, an outbreak of pneumonia of unknown 
aetiology was reported in Wuhan, China [4,5]. This disease problem was then declared as a pandemic by 
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the World Health Organization (WHO) on the 11th March 2020. The coronavirus was identified as the cause 
of this respiratory syndrome, and it was named SARS-CoV-2. The disease that it caused was named COVID-
19. Since then, attention has been given to the use of CQ and HCQ as potential treatments for COVID-19. 
The various mechanisms by which CQ and HCQ may be involved in their antiviral effects have been 
reviewed recently [6] as a result of increased interest due to the COVID-19 pandemic. Potential 
mechanisms include prevention of the virus entering the cells, altering virus replication, inhibiting 
autophagy and modulating the immune response. An interesting antiviral mechanism of CQ and HCQ is that 
they allow Zn ions to enter the cell and act as zinc ionophores [7]. Zinc ions exhibit anticancer and antiviral 
properties by altering the lysosome membrane permeability [8] and the viral RNA-dependent RNA 
polymerase enzyme and thus inhibit the virus replication process inside the cells. 
Figure 1 shows the chemical structures of CQ and HCQ. HCQ has an additional hydroxyl group that 
makes the molecule less lipophilic, reducing the severity of side effects and toxicity. 
  
Chloroquine (CQ) Hydroxy-chloroquine (HCQ) 
Figure 1. The chemical structure of chloroquine (CQ) and hydroxy-chloroquine (HCQ) 
Both compounds are racemic mixtures, but it has been observed that the enantiomers behave 
differently in vivo regarding their pharmacokinetics [9] and metabolism [10]. It has been reported that the 
desethyl CQ excreted by men after treatment with racemic CQ is optically active [11] and that the renal 
clearance of the racemic CQ drug is a stereoselective process [9,12,13]. In vitro efficacy studies did not 
show any difference between the efficacy of the enantiomers [14], but in vivo (rat) studies have shown a 
greater efficacy for the (+)-(S)-CQ than the (-)-R-enantiomer [13,15,16]. More recent article [17] suggests 
chiral switches of enantiomers as more potent forms against Covid-19. It may be explained by the 
stereoselective disposition of CQ and HCQ in vivo. Several studies have already been published on the 
stereoselective blood and plasma protein binding of the two compounds using pure enantiomers [18-20] 
added to plasma and blood.  
The application of chemically bonded chiral stationary phases (Chiralpak HSA and Chiralpak AGP) is a 
powerful tool for separating racemic mixtures [20]. It was found that the CQ enantiomers differ in their 
binding to plasma. The (+)-(S)-CQ has a higher binding to human serum albumin (HSA) than the (-)-(R)-
enantiomer, whereas the latter bound more strongly to α-1-acid-glycoprotein (AGP) than the (+)-(S)-CQ. 
The in vitro human plasma protein binding of HCQ was also enantioselective: the binding of (+)-(S)-HCQ was 
almost 2-fold higher than (-)-(R)-HCQ (64 % against 37 %) [21]. Chromatographic separations of CQ and HCQ 
and their metabolites have been reported using Chiralpak AGP and Chiralpak AD HPLC columns [18,22], 
[23]. Other chromatographic methods have been reported for analytical and preparative separations of CQ 
and HCQ enantiomers [24,25]. 
Biomimetic HPLC properties can be used to estimate the in vivo distribution (volume of distribution, Vd, 
the unbound volume of distribution, Vdu), drug efficiency and various tissue binding properties of 
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compounds [26-28]. The HSA and AGP binding can be measured using Chiralpak HSA and Chiralpak AGP 
HPLC columns (Chiral Technologies Europe, France). In this way, a different estimation of the in vivo 
distribution and tissue binding for the different enantiomers can be obtained supposing they provided two 
requisite peaks from the chromatography, enabling property measurements.  
The aim of this study was to measure the biomimetic properties of CQ and HCQ with special emphasis 
on the different properties of their enantiomers. The other aim was to rationalise the differences in the in 
vivo potency of the enantiomers that were not detected in vitro. A comparison can then be made of the 
estimated tissue binding and distribution data with the published in vivo distribution data. The significance 
of the differences in properties between the (R) and (S) enantiomers can then be evaluated. 
Experimental  
Racemic CQ and HCQ of the highest purity were purchased from Merck (Sigma-Aldrich) and were 
dissolved in DMSO at a 1 mM concentration. The 1 mM solutions were diluted further to 0.1 mM 
concentration from which 10 µL was injected onto the different HPLC columns. 
An Agilent 1100 series HPLC system equipped with an autosampler and diode array detector was used 
for the measurements.  
Measurements of lipophilicity at three pHs 
Gemini NX C-18(2) 5 um columns with dimensions of 3 x 50 mm (Phenomenex Ltd. Macclesfield, UK) 
were used for the determination of the Chromatographic Hydrophobicity Index (CHI) and the CHIlogD 
values [26]. The flow rate was 1.0 mL/min, with starting mobile phases of 0.01 M formic acid (pH 2.6), 
50 mM ammonium acetate adjusted to pH 7.4, and 50 mM ammonium acetate with pH adjusted to 10.5 to 
determine the lipophilicity of the compounds at acidic, neutral and alkaline pHs, respectively. An 
acetonitrile linear gradient was used from 0 to 100 %. The acetonitrile concentration reached 100 % in 
3.5 min. The 100 % acetonitrile mobile phase was maintained for an additional 1 min before it was returned 
to 0 % at 4.7 min. The cycle time of the gradient run was 6 min, with an additional equilibration time of 
1 min before the next injection. The error in the retention time measurements is ±0.005 min in general 
after repeated injections. 
The set of calibration compounds gave an excellent straight line when their retention time data was 
plotted against the predefined CHI values listed in Table 1. 
Table 1. The CHI values of the calibration set of compounds at three pHs [29]. These values were 
obtained by fitting the isocratically determined CHI values and the gradient retention time values. The 
standard error ranged from 0.1 to 0.8 CHI values. The Chromatographic Hydrophobicity Index (CHI) 
approximates the acetonitrile concentration when the compound elutes. It can be converted to the 
octanol/water log D scale using CHIlogD = 0.0525*CHI -1.467. 
Compound CHI at pH 2.6 CHI at pH 7.4 CHI at pH 10.5 
Theophylline 17.9 18.4 5.0 
Phenyl tetrazole 42.2 23.6 16.0 
Benzimidazole 6.3 34.3 30.6 
Colchicine 43.9 45.0 43.9 
Phenyl theophylline 51.7 51.2 51.3 
Acetophenone 64.1 65.1 64.1 
Indole 72.1 71.5 72.1 
Propiophenone 77.4 77.4 77.4 
Butyrophenone 87.3 87.5 87.3 
Valerophenone 96.4 96.20 96.36 
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Measurements of phospholipid-binding at pH 7.4 using an Immobilized Artificial Membrane (IAM) column 
The phospholipid-binding was measured using an IAM PC.DD2 column with dimensions of 100 x 4.6 mm 
(Regis Technologies Inc., Morton Grove, IL, USA). The gradient retention times of the compounds were 
measured using a 50 mM ammonium acetate starting mobile phase with the pH adjusted to 7.4. The mobile 
phase flow rate was 1.5 mL/min. The acetonitrile gradient was applied from 0 min to 4.75 min to reach 
90 %. The 90 % acetonitrile concentration was maintained for an additional 0.5 min (to 5.25 min), then 
returned to 0 % by 5.5 min. The cycle time was 6 min plus an additional 1 min equilibration time was 
applied while the injector prepared for the next injection. The gradient retention times were calibrated 
with the acetophenone homologues for which the CHI IAM values have been established using isocratic 
measurements [26]. The Chromatographic Hydrophobicity Index on the IAM column [CHI(IAM)] 
approximates to the acetonitrile concentration in the mobile phase when the compound elutes. CHI(IAM) 
values above 45 indicate strong phospholipid binding. Repeating the retention time measurements 
provided the error only in the third digit of the minute (±0.005).  
Measurements of plasma protein binding using Chiralpak HSA and AGP columns 
The protein binding measurements were carried out on Chiralpak HSA and Chiralpak AGP columns with 
the dimensions of 3 x 50 mm with 5 um particle size stationary phase (Chiril Technologies Europe, France). 
The mobile phase was 50 mM ammonium acetate adjusted to pH 7.4 with a flow rate of 1.2 mL/min. The 
standard isopropanol (IPA) gradient up to 35 % was achieved in 3.5 min and then maintained for 1 min, 
before returning to 0 % at 4.7 min. The cycle time was 6 min with an additional 1 min re-equilibration time. 
The racemic warfarin showed separation of its enantiomers at retention times of 3.58 and 3.77 mins. The 
reproducibility of the retention time measurements was within ±0.01 min. The calibration set of 
compounds and their literature % binding data that were also converted to log k data are shown in Table 2. 
The racemic CQ and HCQ, however, did not show a separation of their enantiomers under such 
chromatographic conditions and therefore, other gradients and isocratic mobile phases were tested. 
Figures 2a and Figure 2b show the calibration lines obtained for the HSA and AGP binding, respectively. 
The 8 min, “slow gradient” method on the chiral HSA and AGP columns 
To be able to separate the CQ and HCQ enantiomers, the IPA gradient was modified. From 0 to 4 min, 
the IPA concentration was raised from 0 to 15 %, and from 4 to 5 min the 15 % IPA was kept constant 
before it was reduced to 0 % at 5.2 min. The cycle time was 8 min plus an additional 1 min re-equilibration 
time. The same compounds and data that are listed in Table 2 were used to calibrate the retention times; 
however, warfarin, diclofenac and isopropanol could not be eluted under this condition. 
Table 2. The protein binding data of marketed drug molecules that were used to calibrate the retention 
times obtained on the chiral protein columns (Chiralpak HSA and Chiralpak AGP). The % binding data 
obtained by equilibrium dialysis were converted to log k data using log k = log (%binding/(101-%binding). 
Compound name % HSA log k (HSA) 
Retention times 
HSA (tR) 
% AGP log k (AGP) 
Retention times 
AGP (tR) 
Warfarin  97.9 1.5 3.6 83.2 0.7 2.6 
Paracetamol 14.0 -0.8 0.4 3.2 -1.5 0.3 
Nizatidine 20.4 -0.6 0.5 37.1 -0.2 1.3 
Trimethoprim 37.6 -0.2 1.0 46.2 -0.1 1.5 
Propranolol 66.6 0.3 1.4 86 0.8 2.8 
Carbamazepine 75.0 0.5 1.6 65 0.3 2.1 
Nicardipine 95.0 1.2 2.9 87 0.8 2.9 
Indomethacin 99.5 1.8 4.5 56 0.1 1.8 
Diclofenac 99.8 1.9 4.3 60 0.2 1.9 
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Figure 2. The calibration line obtained on the Chiralpak HSA (a) and Chiralpak AGP (b) columns by plotting the 
logarithmic value of the obtained retention times and the log k values derived from the literature % binding 
data [30,31] 
Isocratic measurements of CQ and HQ on Chiralpak HSA column 
As the CQ and HCQ enantiomers were not separated using the longer IPA gradient, isocratic analyses 
were also carried out using a 1.2 mL/min flow rate with 5, 8 and 10 % IPA, respectively. Using 5 % IPA in the 
mobile phase, only paracetamol and propranolol eluted from the calibration set of compounds. When 10 % 
IPA was used warfarin, propranolol and nicardipine were eluted and their respective retention times were 
used to create a calibration curve for the calculation of the binding of CQ and HCQ from their obtained 
retention times using the same HPLC conditions.  
Measurements of human plasma protein binding by rapid equilibrium dialysis (RED) 
The test compounds were prepared in 100 % pooled human plasma. The measurement was performed 
using equilibrium dialysis with the two compartments separated by a semi-permeable membrane. The 
plasma solution was added to one side of the membrane while buffer (pH 7.4) was added to the other side. 
The system was allowed to reach equilibrium at 37 °C. Compound concentration on both sides of the 
membrane was measured by LC-MS/MS, and the fraction of unbound compound calculated. Calibration 
standards were prepared in plasma and buffer. Test compound incubations were performed in triplicate. A 
control compound was included in each experiment. The solutions for each batch of compounds were 
combined into two groups (protein-free and protein-containing). Cassette analysed by LC-MS/MS using two 
sets of calibration standards for protein-free solutions (7 points) and protein-containing solutions (7 
points). The experiments were carried out at Cyprotex Discovery Ltd (UK) and repeated at Sygnature 
Discovery Ltd (UK) laboratories using their generic LC/MS method. The unbound fraction (fu) is calculated 
from the concentration of the test compound in the protein-containing side Cp and the protein-free side Cf 
based on the formula: 
fu= 1 – (Cp-Cf)/Cp . 
Results and Discussion 
The lipophilicity of compounds is an important physicochemical property that may explain the protein 
binding, the volume of distribution and other distribution properties of drug molecules. It is usually 
characterised by octanol/water partition (log P) and distribution (log D) coefficients. The log P refers to the 
neutral form of the molecule, while log D refers to the compound’s distribution between octanol and water 
at physiological pH (pH 7.4).  
The calculated and measured physicochemical properties of CQ and HCQ are listed in Table 3. 
 
(a) (b) 
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Table 3. Literature and calculated data for CQ and HCQ 
It can be seen in Table 3 that the 
measured and calculated lipophilicity 
values vary a lot. In almost all cases, HCQ 
is less lipophilic due to the hydrophilic 
hydroxy group that also affects the 
basicity of this compound. Comparing the 
log D and log P values, it is apparent that 
a high percentage of both molecules are 
ionised (positively charged) at pH 7.4. The measured CHI log P may well be underestimating the lipophilicity 
as the pKa values are around 10. Therefore, the mobile phase applied pH 10.5 may not suppress the 
ionisation of both molecules completely, and the actual lipophilicity of the neutral form of these molecules 
can be much greater. 
Table 4 shows the measured phospholipid and protein binding data of the two compounds obtained 
using the standard 6 min protocol [26]. 
It can be seen from Table 4 that HCQ has marginally weaker binding to phospholipids and plasma 
proteins. The enantiomers could not be separated on the chiral HSA and AGP stationary phases using the 
standard high-throughput protocol for biomimetic property measurements. The phospholipid-binding is in 
a medium-strong range. It has been reported that compounds that have CHI IAM values greater than 50 
have the potential for promiscuous binding and causing phospholipidosis [34]. The hERG inhibition, which is 
an indicator for causing arrhythmia and heart condition, is also associated with lipophilic and positively 
charged compounds [35]. Positively charged compounds usually have stronger binding to IAM than 
isolipophilic compounds without the presence of positive charge [36]. However, the CHI IAM values of CQ 
and HCQ are below 50. The measured protein binding was greater than has been published [19], ranging 
from 46 to 74 % in patients with rheumatoid arthritis. Strong AGP binding was also observed, being 
approximately the same as the albumin binding.  
Table 4. The measured phospholipid binding (CHI IAM), protein binding and estimated 
total plasma protein binding (PPB) based on the % HSA and % AGP binding and the 
lipophilicity of the compounds. The error of the values depends on the model error and 
the error obtained from fitting the calibration lines. The CHI IAM values are reproducible 
with ±3 CHI unit, the protein binding % error is larger at the middle range (± 10 %) and 
much smaller above 90 % binding (±0.1 %), the estimation of the total plasma protein 
binding includes the model error of ± 0.36 in log k PPB values. 
Property CQ HCQ 
CHI (IAM) 47 45.4 
log k (IAM) 2.6 2.5 
% HSA bound 87.6 84.9 
log k HSA 0.8 0.7 
% AGP bound 88.8 89.0 
log k AGP 0.9 0.9 
Estimated % plasma protein binding (PPB) 94.8 93.4 
log k PPB 1.2 1.1 
However, the AGP concentration in the plasma ranges from 1 to 10 % while the albumin concentration 
in the plasma is around 60 %, being the most abundant protein. It is also well established that AGP prefers 
to bind to positively charged compounds since it has negatively charged sialic acids at its binding site [37]. 
The lysosomes inside the cell also contain glycoproteins that are negatively charged and attract positively 
Property CQ HCQ 
ACD log P (calculated) 4.69 3.77 
Chemaxon log P (calculated) 3.93 2.89 
ACD log D (calculated) 1.74 1.96 
Chemaxon log D (calculated) 0.88 0.33 
Measured log I (ChemSpider [32, 33]) 2.68 -4.63 1.55 – 3.85 
CHI log D (pH 7.4)  0.79 0.66 
CHI log P 2.68 2.13 
Chemaxon pKs (calculated) 10.32 9.76 
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charged compounds. The strong AGP binding of CQ and HCQ may explain the large variability of the plasma 
protein binding data as the AGP concentration depends on the disease state and it can increase significantly 
in inflammation, cancer and with age [38].  
Table 5 shows the equations of the models that were used to make estimations of the in vivo properties 
of the drugs from the measured biomimetic HPLC data. Note, that the log k HSA and log k IAM data had to 
be transformed to log K HSA and log K IAM data as the measured log k data for acetophenone homologues 
up to octanophenone did not show linear correlation with their octanol water partition coefficients (log P) 
[39]. For the mechanistic model of the volume of distribution, we converted both the measured albumin 
and phospholipid binding data so that they showed linear correlation with the linear free-energy related 
log P values. Thus, the regression coefficients in linear regression analysis are meaningful and reflect to the 
physiological proportion of the albumin and phospholipids in the body. The estimated distribution and 
tissue binding data for CQ and HCQ were evaluated using the standard 6-min HPLC based measurements of 
biomimetic properties (CHIlogD at three pHs, log k HSA, log k AGP and log k IAM). They are based on the 
calibrated retention times obtained on C-18, IAM, Chiralpak HSA and Chiralpak AGP columns. The total 
plasma protein binding, lung tissue binding, drug efficiency, brain tissue binding and brain to blood ratio, 
cell partition coefficient and lung tissue binding have been calculated using the equations listed in Table 5 
and are shown in Table 6. 
Table 5. The published and validated model equations that are used together with the measured 
properties to estimate the in vivo distribution behaviour of drugs. (abbreviations: IAM = Immobilized 
Artificial Membrane; HSA = Human Serum Albumin; Vd = volume of distribution; Vdu = Unbound volume of 
distribution, DEmax = maximum drug efficiency; BTB = brain tissue binding; PPB = plasma protein binding, fu 
= unbound fraction; Kbb = brain to blood partition coefficient; Kpcell = cell partition coefficient; LTB = lung 
tissue binding) 
log K IAM [43] = 0.29*e(0.026CHI(IAM)+0.42) +0.7 
log k IAM [43] = 0.046*CHI(IAM)+0.42 
Phospholipidotic potential (CAD-
likeness) 
= CHI (IAM) + (CHI at pH 10.5 – CHI at pH 7.4) 
log K HSA [43] = elog k(HSA)  
log k HSA [30] = log (%HSAbound/(101- %HSA bound))  
Estimated log Vd [43,44] = 0.44*log K IAM -0.22*log K HSA – 0.62  
Estimated log Vdu[27] = 0.23*log K HSA +0.43*log K IAM -0.72  
DEmax [45] = 100/Vdu  
log k BTB [31] = 1.29*log k IAM+1.03*log k HSA-2.37 
log k (PPB)[31] = 0.98∗log 𝑘 𝐻𝑆𝐴+0.19∗log 𝑘 𝐴𝐺𝑃+0.031∗CHI log D 7.4−0.20  
%BTB [31] = 100*10log k BTB/(1+10log k BTB) 
%PPB [31] = 100*10log k PPB/(1+10log k PPB) 
fu BTB and PPB [31] = (100-%BTB)/100 and (100 %-%PPB)/100 
Kbb [31] = fuPPB/fuBTB 
log Kpcell [46] = 1.1log k IAM-1.9 
log k LTB [31] = 0.49*log k PPB+0.34CHIlog D-0.069 





It can be seen from Table 6 that both compounds have CAD-likeness values greater than 50, which 
indicates that both have phospholipidotic potential. It is known that chloroquine causes phospholipidosis 
both in animals and in human [40-42]. However, the phospholipidotic potential of HCQ is much less than 
CQ. Although the phospholipid-bindings (CHI IAM) were not very different, the greater difference in CAD-
likeness values is due to the larger percentage of the positively charged form of CQ than in HCQ. It is 
obvious from the lower acid dissociation constant of HCQ and the smaller difference between the CHIlogP 
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and CHIlogD values (see Table 3). It also implies that HCQ is less likely to cause hERG inhibition and 
promiscuous binding and in general, fewer side effects. Based on the measured data, the expected brain 
tissue binding did not show a significant difference between CQ and HCQ. On the contrary, the brain to 
blood ratio is smaller in HCQ than CQ due to the slightly stronger AGP binding of HCQ that keeps the 
compound in the plasma compartment.  
Table 6. The estimated biomimetic properties of CQ and HCQ  
Interestingly the expected volume of 
distribution based on the measured biomimetic 
properties is 6.9 and 5.8 L/kg for CQ and HCQ, 
respectively, which is not as high as over 100 L/kg 
as has been described in the literature [16,47-
49]. The Vd of CQ was 116 to 285 L/kg in healthy 
volunteers while HCQ was reported to have a 
much higher volume of distribution at above 
4000 L/kg [48]. Tett et al. [50], reported a range 
of steady-state Vd values for HCQ ranging from 
2402 to 8346 L that are equivalent to 34.3 to119 L/kg. The volume of distribution was 5 to 7 times greater 
when the plasma concentration was considered instead of the blood concentration as the blood/plasma 
ratio was reported to be 5 to 7. The reported plasma protein binding value that was determined in 1986 
was 66.6 % [20]; enantioselective plasma protein binding, albumin and AGP binding were also reported. 
The human plasma protein binding measurements were repeated using the rapid equilibrium dialysis 
method and the obtained average values were 52.6 % (±6.2 %) and 30.7 % (±11.3 %) for CQ and HCQ, 
respectively. The estimated plasma protein binding based on the biomimetic HPLC measurements was 
much stronger (95 % and 93 % for CQ and HCQ, respectively) than that published using in vivo data. At this 
stage, there is no explanation for the difference. This is the cause of the much lower estimated volume of 
distribution. 
The AGP binding using equilibrium dialysis method was reported to be 48.4 % (59.9 and 34.9 % of the R 
and S enantiomers, respectively) for CQ and 34 % (29 and 41 % for the R and S enantiomer, respectively) for 
HCQ [51]. The albumin binding was only 38.6 and 40 % for CQ and HCQ, respectively, by the same author 
[51]. These values were quoted from earlier publications where the actual measurements were originally 
reported [52-54]. It was observed that under the standard IPA gradient conditions, both CQ and HCQ eluted 
between Carbamazepine and Nicardipine, being closer to Nicardipine, which binds to plasma proteins at 75 
and 95 %, respectively. This explains why the HSA binding was calculated as being 87 and 83 % (see Table 
3). The DEmax values reveal the free plasma concentration relative to the dose. Most marketed drug 
molecules have DEmax values of around 1 %. It can be seen that both CQ and HCQ have greater than 1 % 
drug efficiency, which indicates that a high free concentration can be achieved with a relatively low dose. 
The estimated lung tissue binding for both CQ and HCQ was weaker than their brain tissue binding. As 
mucus binding correlates very well with the AGP binding, strong mucus binding can be expected for both 
compounds. The cellular partition coefficients of both compounds are high (Kpcell above 7), which means a 7 
to 8 times greater concentration than the intracellular concentration can be expected for both compounds. 
Unfortunately, our standard fast gradient protocols used for the HSA and AGP binding measurements 
did not allow the separation of the enantiomers of CQ or HCQ. This is also an indication that there are no 
significant differences in the biomimetic properties of each respective enantiomer. Therefore, new HPLC 




%BTB 98.4 97.6 
est log k BB 0.9 0.8 
Brain to plasma 3.4 2.8 
Vd (L/kg) 6.9 5.1 
Vdu (L/kg) 56.1 38.8 
DEmax% 1.8 2.6 
% LTB 96.3 93.9 
Kpcell 8.7 7.3 
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conditions were evaluated on the Chiralpak HSA and Chiralpak AGP column by increasing the gradient 
analysis time and reducing the maximum IPA concentration in the mobile phase. Slowing down the gradient 
to reach 10 and 20 % IPA did not result in the separation of the enantiomers on the HSA column, and both 
CQ and HCQ eluted after Carbamazepine (75 % plasma protein binding). The calculated HSA binding was 
82.2 and 81.9 % for CQ and HCQ, respectively. Isocratic measurements using 5, 8 and 15 % IPA in the 
mobile phase resulted in 80 % binding when the relative retention times obtained using a partial set of 
calibration compounds were taken into consideration. No separation of the enantiomers was observed. 
Figure 3 shows the chromatograms of CQ and HCQ obtained on a ChiralPak HSA column using %IPA in 
isocratic mode. However, no separation of enantiomers was observed.  
  
Figure 3. The chromatograms of CQ (a) and HCQ (b) on ChiralPak HSA column using 0 % IPA in the mobile 
phase in isocratic mode. 
When similar changes in the mobile phases were applied using the Chiralpak AGP column, excellent 
separations of both the CQ and HCQ enantiomers were observed albeit with a very short column size (L=50 
mm) and fast flow rate (1.2 mL/min). It can be seen in Figure 4 that the separation of enantiomers occurred 
under the shallower gradient conditions. Still, no significant differences between the retention times were 
observed for CQ and HCQ confirming that the AGP binding of the two molecules is quite similar. The chiral 
separations were also obtained in the isocratic mode. However, the difference in binding between the 
enantiomers was only 3 to 4 %. Based on these measurements, the AGP binding is much stronger for both 
CQ and HCQ than previously reported. When the AGP binding is above 80 %, the compounds are expected 
to have variable efficacy in the clinic. It is because the AGP concentration changes in various disease states 
and it can alter the total plasma protein binding significantly, and that may cause a reduction of the free 
therapeutic concentration of the drugs.  
  
Figure 4. The chromatogram of racemic Chloroquine (CQ) (a) and hydroxychloroquine (HCQ) (b) obtained 
using the shallower gradient method (“slow gradient”) with 0 to 15 % IPA over 4.0 min and then maintained 
at 15 % for 1 min before returning to 0 % IPA on a Chiralpak AGP column (50 x 3 mm) with a 1.2 ml/min flow 
rate. The enantiomers are identified based on ref [51] that reported CQ (R) and HCQ (S) as the stronger 
binders to AGP. 
(a) (b) 
(a) (b) 
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Table 7 shows the % binding data obtained using a slow gradient (up to 15 % IPA). The protein binding 
measurements were repeated using isocratic conditions with 5, 8 and 15 % IPA in the mobile phase. Under 
such conditions, stronger binding compounds from the calibration mixture (warfarin, indomethacin and 
diclofenac) could not be eluted. The retention times of CQ and HCQ obtained when using 5, 8 and 15 % IPA 
on Chiralpak HSA and Chiralpak AGP columns are listed in Table 8. 
Table 7. The measured and estimated biomimetic properties of CQ and HCQ based on the data 
obtained using the slower and shallower gradient (up to 15 % IPA). 
Property (+)-S CQ (-)-R CQ (+)-S HCQ (-)-R HCQ 
% bound HSA 82.2 82.2 81.9 81.9 
% bound AGP 85.0 88.4 88.5 84.3 
calc%PPB 90.6 91.1 91.2 91.7 
CHI log D2 -1.2 -1.2 -1.3 -1.3 
CHI log D7.4 0.8 0.8 0.7 0.7 
CHI log D10.5 2.7 2.7 2.1 2.1 
CHIlog P 2.7 2.7 2.1 2.1 
CHI IAM 46.9 46.9 45.4 45.4 
CAD-likeness 82.9 82.9 73.6 7367 
%BTB 97.6 97.6 97.1 97.0 
est log k BB 0.9 0.9 0.9 0.8 
Brain to plasma 4.0 3.8 3.0 2.8 
Vd L/kg 8.2 8.2 6.4 6.3 
Vdu 45.7 45.8 35.3 35.1 
DEmax% 2.2 2.2 2.8 2.9 
% lung tissue binding 95.5 95.6 93.1 93.3 
Table 8. The retention times obtained for CQ and HCQ (enantiomers) using a 1.2 mL/min flow rate and 5, 8 and 15 
% IPA on Chiralpak HSA and Chiralpak AGP columns. The calculated % binding data are also given in brackets. The 
retention times of Propranolol and Nicardipine, the two basic compounds from the calibration set, are also shown. 
The last two rows in the table are the data from reference [51] where the values were obtained using an 
equilibrium dialysis method (n/a means not applicable) 
Compound/Cond. CQ (R) CQ (S) HCQ (R) HCQ (S) 
propranolol 
(66 % PPB) 
nicardipine  
(96 % PPB) 
HSA 5 % IPA (min) 0.89 (60 %) 1.15 (68 %) 0.94 (61 %) 1.4 (73 %) 0.76 (54 %) 6 (96 %) 
HSA 8 % IPA (min) 0.87 (64 %) 0.87 (64 %) 0.91 (66 %) 0.91 (66 %) 0.73 (57.6 %) 3.39 (95 %) 
HSA 15 % IPA (min) 0.68 (80 %) 0.68 (80 %) 0.69 (80 %) 0.69 (80 %) 0.58 (66 %) 1.05 (95 %) 
AGP 5 % IPA (min) 3.84 (86 %) 5.24 (90 %) 3.84 (86 %) 5.4 (90 %) 2.78 (85 %) >8 min (>98 %) 
AGP 8 % IPA (min) 2.53 (84 %) 2.55 (84 %) 2.95 (85 %) 3.85 (87 %) 1.73 (68 %) 5.63 (98 %) 
AGP 15 % IPA (min) 2.20 (82 %) 2.00 (81 %) 1.98 (81 %) 2.23 (83 %) 1.58 (67 %) 5.0 (96 %) 
% HSA bound [51] 30 % 54 % 50 % 29 % n/a n//a 
% AGP bound [51] 59 % 35 % 29 % 34 % n/a n/a 
It can be seen in Table 8 that the estimated % binding data using the retention time measured for the 
partial calibration set of compounds changes depending on the experimental conditions. The HSA binding 
ranged from 60 to 80 % but generally was much greater than the published albumin (HSA) and alpha-1-acid 
glycoprotein (AGP) binding data. This is because the retention times dependency on the IPA concentration 
was greater for the calibration set of compounds than for the CQ and HCQ. Table 9 shows the measured 
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and estimated biomimetic properties of CQ and HCQ based on the data obtained when using the isocratic 
method on the Chiralpak HSA and Chiralpak AGP column (IPA concentration 15 %). Probably, CQ and HCQ 
do not bind to the hydrophobic site on the albumin but could bind to a specific area that is not affected 
strongly by the IPA concentration. The AGP binding was also much stronger using the biomimetic 
methodology that converts the % binding to the total plasma protein concentration where the AGP 
concentration is only 1 to 3 %. The difference can be explained by the different scaling used when 
expressing the % of the compound bound in plasma or to a single protein. However, when using the lowest 
IPA concentration in the mobile phase (5 %), the data obtained was between 77 and 87 % for the 
enantiomers of CQ and HCQ. The in vivo PK data also showed large individual variations in humans which 
suggests that these compounds may bind to a particular type of negatively charged proteins in plasma and 
in tissues that may have large concentration variations. 
Table 9. The estimated in vivo properties of CQ and HCQ enantiomers obtained from the data 
when the protein binding was obtained with the 15 % IPA isocratic conditions. 
Property (+)- S CQ (-)- R CQ (+)- S HCQ (-)-R HCQ 
% bound HSA 79.9 79.9 79.9 79.9 
% bound AGP 82.0 81.0 85.1 87.3 
calc% PPB 89.9 89.7 89.0 88.9 
CHI logD2 -1.2 -1.2 -1.3 -1.3 
CHI logD7.4 0.8 0.8 0.7 0.7 
CHI logD10.5 2.7 2.7 2.1 2.1 
CHIlogP 2.68 2.7 2.1 2.1 
CHI IAM 46.92 46.9 45.4 45.4 
CAD-likeness 82.89 82.9 73.6 73.6 
%BTB 97.26 97.3 96.7 96.7 
est log k BB 0.96 1.0 0.9 0.9 
Brain to plasma 4.06 4.0 3.1 3.0 
log Vd 0.94 0.9 0.8 0.8 
Vd L/kg 8.65 8.7 6.7 6.6 
log Vdu 1.63 1.6 1.5 1.5 
Vdu 43.01 43.0 33.5 33.3 
DEmax% 2.33 2.3 23.0 3.0 
% lung tissue binding  96.05 95.1 92.6 92.7 
It can be seen that the estimated distribution data shown in Table 7 and Table 9 are very similar, and do 
not differ significantly despite the large differences in the % protein binding data. It is important to note 
that the % binding data are not linearly related to the protein binding partition coefficients. Still, they have 
a sigmoidal relationship with the log k and logarithmic retention time data. This means that small variations 
in the log k HSA and log k AGP values result in a large variation when expressed as percentage binding in 
the range of 30 to 80 %. In the stronger binding range, large variations in retention times will result in only 
a small per cent of change. The biomimetic protein binding data have been validated for differentiating 
between strong binders and are more accurate in that region [30]. 
Conclusions 
CQ and HCQ have gained renewed interest as potential cures for COVID-19 when used in combination 
with antibiotics and zinc. Biomimetic properties derived from biomimetic HPLC stationary phases have 
never been measured for these compounds. CQ and HCQ did not show extreme phospholipid-binding that 
would give the compounds a negative toxicity profile. CQ and HCQ bind to AGP very strongly and stereo-
selectively, though there is no significant difference between CQ and HCQ in this regard. The 
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stereoselective binding to AGP did not result in significant differences in the estimated total plasma protein 
binding, lung tissue binding and volume of distribution. The retention time measurements are very 
reproducible on the biomimetic columns, but the absolute values of the calculated binding data originate 
from the error of the calibration line fit. However, the order of the retention data is very reproducible. The 
in vivo distribution models include 0.5 to 1 log unit errors but again the rank order of the compounds is 
reproducible. The comparison between the estimated distribution properties and the properties published 
in the literature show great variations, however the biomimetic protein binding data were greater than the 
measured plasma protein binding data obtained by equilibrium dialysis. The aim of the study was to 
differentiate the binding of the various enantiomers and estimate the in vivo distribution of each 
enantiomer. It was found that the small differences in the protein binding data did not manifest itself in 
significant differences in the predicted in vivo distribution data, so this cannot explain the observed 
differences in the in vivo activity of the enantiomers. It was found that the drugs bind to glycoproteins that 
are present in humans in variable amounts from various disease states, which may explain the big 
variations observed in the in vivo distribution and protein binding data. 
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